GPT and metabolic dysfunction-associated steatotic liver disease: Zhong et al. completed a meta-analysis of eight randomized controlled trials (RCTs) studying NAFLD, and concluded that silymarin had statistically significant effect in reducing AST and ALT levels in patients [24].